Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Trial Profile

Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HOMER
  • Sponsors GlaxoSmithKline; Novartis
  • Most Recent Events

    • 19 Feb 2017 This trial has been completed in France (end date: 19 Dec 2016).
    • 11 Feb 2017 This trial has been completed in Slovakia (end date: 19 Dec 2016).
    • 08 Feb 2017 This trial has been completed in Belgium (end date: 19 Dec 2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top